Name
As of 03/25/2024Price
Aum/Mkt Cap
YIELD
Exp Ratio
Watchlist
Vitals
YTD Return
-2.6%
1 yr return
-0.8%
3 Yr Avg Return
-0.5%
5 Yr Avg Return
N/A
Net Assets
$103 M
Holdings in Top 10
44.1%
52 WEEK LOW AND HIGH
Expenses
OPERATING FEES
Expense Ratio 1.75%
SALES FEES
Front Load N/A
Deferred Load N/A
TRADING FEES
Turnover N/A
Redemption Fee N/A
Min Investment
Standard (Taxable)
$2,500
IRA
$2,500
Fund Classification
Fund Type
Open End Mutual Fund
Name
As of 03/25/2024Price
Aum/Mkt Cap
YIELD
Exp Ratio
Watchlist
LYFIX - Profile
Distributions
- YTD Total Return -2.6%
- 3 Yr Annualized Total Return -0.5%
- 5 Yr Annualized Total Return N/A
- Capital Gain Distribution Frequency N/A
- Net Income Ratio -0.96%
- Dividend Yield 0.0%
- Dividend Distribution Frequency Annual
Fund Details
-
Legal NameAlphaCentric LifeSci Healthcare Fund
-
Fund Family NameMutual Fund Series Trust
-
Inception DateNov 29, 2019
-
Shares OutstandingN/A
-
Share ClassI
-
CurrencyUSD
-
Domiciled CountryUS
-
ManagerMark Charest
Fund Description
The Fund seeks to achieve its investment objective by investing in the life sciences and healthcare related companies that the Funds investment sub-advisor, LifeSci Fund Management LLC (the Sub-Advisor), believes to have potential to appreciate in value. Under normal market conditions, the Fund invests at least 80% of its net assets plus borrowings for investment purposes in the securities of companies in the life sciences and healthcare sectors, which the Fund defines to be the category of companies related to producing or supplying facilities, supplies, technology, pharmaceuticals, equipment, devices or services for the preservation and care of a persons or animals health. The Fund invests in equity securities, primarily common stock, of these companies and may also invest, from time to time, in exchange traded funds (ETFs) that primarily invest in these companies. The Fund defines life sciences and healthcare companies to include those companies that are expected to derive 50% or more of their revenue from life sciences and healthcare related products and services. These companies may include development stage companies, which are entities devoting substantially all of their efforts establishing a business for which commercial operations have not commenced or no significant revenue is being generated.
The Fund may invest up to 15% of the Funds net assets in private and other companies whose securities may have legal or contractual restrictions on resale or are otherwise illiquid such as initial public offerings (IPOs), mezzanine financing offerings and other structured transactions. The Fund may invest in securities of companies of any market capitalization and in foreign companies either directly or through American Depositary Receipts (ADRs).
The Fund concentrates its investments (i.e., invests more than 25% of its assets) in the biotech and pharmaceutical; health care facilities and services; and medical equipment and devices industries, collectively. Each of these industries are commonly categorized within the healthcare sector because they share similar distribution channels and regulatory constraints.
For hedging purposes or when the Sub-Advisor anticipates significant price changes due to company or market moving events, the Fund may also invest in inverse ETFs and purchase and sell call and put options on equity securities of life sciences and healthcare companies.
The Sub-Advisor begins the investment selection process by systematically screening the universe of life sciences and healthcare companies using fundamental scientific and medical literature review, and input from leading scientific and medical experts to identify highly innovative thematic areas of interest. Financial analysis, market projections and corporate diligence are then performed to select the Funds investments.
The Fund actively trades its portfolio investments, which may lead to higher transaction costs that may affect the Funds performance.
LYFIX - Performance
Return Ranking - Trailing
Period | LYFIX Return | Category Return Low | Category Return High | Rank in Category (%) |
---|---|---|---|---|
YTD | -2.6% | -15.0% | 17.3% | 95.71% |
1 Yr | -0.8% | -20.2% | 35.0% | 92.02% |
3 Yr | -0.5%* | -30.8% | 14.0% | 72.44% |
5 Yr | N/A* | -3.5% | 14.3% | N/A |
10 Yr | N/A* | 0.2% | 14.1% | N/A |
* Annualized
Return Ranking - Calendar
Period | LYFIX Return | Category Return Low | Category Return High | Rank in Category (%) |
---|---|---|---|---|
2023 | 4.4% | -12.6% | 19.0% | 26.38% |
2022 | -5.1% | -53.9% | 3.2% | 11.54% |
2021 | -14.7% | -39.6% | 24.2% | 76.28% |
2020 | 51.3% | -13.6% | 178.2% | 5.30% |
2019 | N/A | 3.8% | 63.8% | N/A |
Total Return Ranking - Trailing
Period | LYFIX Return | Category Return Low | Category Return High | Rank in Category (%) |
---|---|---|---|---|
YTD | -2.6% | -15.0% | 17.3% | 95.71% |
1 Yr | -0.8% | -20.2% | 35.0% | 92.02% |
3 Yr | -0.5%* | -30.8% | 14.0% | 72.44% |
5 Yr | N/A* | -3.5% | 14.3% | N/A |
10 Yr | N/A* | 0.2% | 14.1% | N/A |
* Annualized
Total Return Ranking - Calendar
Period | LYFIX Return | Category Return Low | Category Return High | Rank in Category (%) |
---|---|---|---|---|
2023 | 7.2% | -12.6% | 19.0% | 26.38% |
2022 | -0.8% | -53.9% | 3.7% | 5.77% |
2021 | -3.3% | -33.9% | 26.0% | 82.05% |
2020 | 54.8% | -0.7% | 180.6% | 3.31% |
2019 | N/A | 4.6% | 63.8% | N/A |
NAV & Total Return History
LYFIX - Holdings
Concentration Analysis
LYFIX | Category Low | Category High | LYFIX % Rank | |
---|---|---|---|---|
Net Assets | 103 M | 6.16 M | 45 B | 77.91% |
Number of Holdings | 55 | 23 | 413 | 75.46% |
Net Assets in Top 10 | 46 M | 2.07 M | 20.4 B | 74.23% |
Weighting of Top 10 | 44.12% | 18.1% | 77.0% | 65.64% |
Top 10 Holdings
- FIRST AM-TR OB-X 11.31%
- GALAPAGOS NV-ADR 4.10%
- BIOCRYST PHARMACEUTICALS 3.88%
- PACIRA BIOSCIENC 3.80%
- UNITED THERAPEUT 3.80%
- HARMONY BIOSCIE 3.78%
- EMBECTA CORP 3.63%
- IMMUNOGEN INC 3.63%
- COHERUS BIOSCIEN 3.19%
- WALGREENS BOOTS 3.01%
Asset Allocation
Weighting | Return Low | Return High | LYFIX % Rank | |
---|---|---|---|---|
Stocks | 87.68% | 87.17% | 106.13% | 96.93% |
Cash | 12.32% | 0.00% | 32.99% | 4.91% |
Preferred Stocks | 0.00% | 0.00% | 7.86% | 39.88% |
Other | 0.00% | -22.99% | 17.73% | 38.65% |
Convertible Bonds | 0.00% | 0.00% | 0.37% | 18.35% |
Bonds | 0.00% | 0.00% | 12.39% | 23.31% |
Stock Sector Breakdown
Weighting | Return Low | Return High | LYFIX % Rank | |
---|---|---|---|---|
Healthcare | 100.00% | 59.26% | 100.00% | 7.59% |
Utilities | 0.00% | 0.00% | 0.00% | 11.39% |
Technology | 0.00% | 0.00% | 22.69% | 17.72% |
Real Estate | 0.00% | 0.00% | 5.89% | 15.19% |
Industrials | 0.00% | 0.00% | 7.02% | 17.09% |
Financial Services | 0.00% | 0.00% | 1.60% | 35.44% |
Energy | 0.00% | 0.00% | 0.00% | 11.39% |
Communication Services | 0.00% | 0.00% | 9.11% | 14.56% |
Consumer Defense | 0.00% | 0.00% | 25.73% | 22.78% |
Consumer Cyclical | 0.00% | 0.00% | 1.92% | 17.09% |
Basic Materials | 0.00% | 0.00% | 7.16% | 41.77% |
Stock Geographic Breakdown
Weighting | Return Low | Return High | LYFIX % Rank | |
---|---|---|---|---|
US | 87.68% | 66.21% | 104.41% | 66.87% |
Non US | 0.00% | 0.00% | 29.78% | 60.12% |
LYFIX - Expenses
Operational Fees
LYFIX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
---|---|---|---|---|
Expense Ratio | 1.75% | 0.08% | 4.28% | 24.54% |
Management Fee | 1.25% | 0.03% | 1.25% | 98.77% |
12b-1 Fee | 0.00% | 0.00% | 1.00% | 1.28% |
Administrative Fee | N/A | 0.03% | 0.25% | N/A |
Sales Fees
LYFIX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
---|---|---|---|---|
Front Load | N/A | 3.50% | 5.75% | N/A |
Deferred Load | N/A | 1.00% | 5.00% | N/A |
Trading Fees
LYFIX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
---|---|---|---|---|
Max Redemption Fee | N/A | 1.00% | 1.00% | N/A |
Related Fees
Turnover provides investors a proxy for the trading fees incurred by mutual fund managers who frequently adjust position allocations. Higher turnover means higher trading fees.
LYFIX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
---|---|---|---|---|
Turnover | N/A | 0.00% | 238.00% | 97.50% |
LYFIX - Distributions
Dividend Yield Analysis
LYFIX | Category Low | Category High | LYFIX % Rank | |
---|---|---|---|---|
Dividend Yield | 0.00% | 0.00% | 6.95% | 13.50% |
Dividend Distribution Analysis
LYFIX | Category Low | Category High | Category Mod | |
---|---|---|---|---|
Dividend Distribution Frequency | Annual | Annual | Monthly | Annual |
Net Income Ratio Analysis
LYFIX | Category Low | Category High | LYFIX % Rank | |
---|---|---|---|---|
Net Income Ratio | -0.96% | -2.54% | 1.85% | 87.82% |
Capital Gain Distribution Analysis
LYFIX | Category Low | Category High | Capital Mode | |
---|---|---|---|---|
Capital Gain Distribution Frequency | Annually | Annually | Annually |
Distributions History
Date | Amount | Type |
---|---|---|
Dec 15, 2023 | $0.340 | OrdinaryDividend |
Dec 16, 2022 | $0.549 | OrdinaryDividend |
LYFIX - Fund Manager Analysis
Managers
Mark Charest
Start Date
Tenure
Tenure Rank
Nov 29, 2019
2.5
2.5%
Dr. Charest has served as a portfolio manager of LifeSci Fund Management since 2019. In 2017, he founded Phenomic Capital LLC to provide investment advice and consulting services focused on the healthcare sector. In 2019 Phenomic Capital became an affiliated majority owner of the LifeSci Fund Management. From 2015 to 2016, Mark was SVP at Tekla Capital Management, focused on public and private healthcare technology investments. Between 2012 and 2015, he was Portfolio Manager at New Leaf Venture Partners, focused on public healthcare technology investments. From 2010 to 2012, Dr. Charest was a Kauffman Fellow at Panorama Capital where he served on the board of directors of Itero Biopharmaceuticals and was a board observer at Presidio Pharmaceuticals and PowerVision. Dr. Charest is an inventor on eight drug patents. Prior to his investment career, he held an operating role in the oncology area as a Medicinal Chemistry Lab Manager at the Novartis Institutes for BioMedical Research. Dr. Charest earned his PhD in chemistry and chemical biology from Harvard University as a National Science Foundation Graduate Research Fellow, his MS in chemistry and chemical biology from Harvard University, and his BA in chemistry, with Highest Honors, from Rutgers University.
Tenure Analysis
Category Low | Category High | Category Average | Category Mode |
---|---|---|---|
0.02 | 24.72 | 7.84 | 0.25 |